Toga Limited’s Majority-Owned Subsidiary, Eostre Berhad is Appointed as the Exclusive Worldwide Distributor for Shenzhen Shengquan Biotechnology Co Ltd

PETALING JAYA, Malaysia, June 18, 2021 (GLOBE NEWSWIRE) — Eostre Berhad, a majority-owned subsidiary of Toga Limited (OTC: TOGL), has been officially appointed by China’s Shenzhen Shengquan Biotechnology Co., Ltd., as its exclusive worldwide distributor for its product, the “H2O Energy Bottle”.

Eostre is now tasked with developing a world-wide market for the “H2O energy bottles”.

“We are pleased to establish this collaboration between Shenzhen Shengquan Biotechnology and Eostre. This collaboration will further grow Eostre’s product range and customer base globally,” said Eostre Berhad General Manager, Ms. Low Kah Fong.

“We anticipate both companies will jointly expand the awareness and demand for the H2O energy bottle. This is also seen as being in line with Eostre’s vision of becoming an international brand with world-leading innovative healthcare products” said Ms Low.

Contact:

Alexander D. Henderson
TOGA LIMITED, 515 S. Flower Street, 18th Floor, Los Angeles, CA 90071
(949) 333-1603
info@togalimited.com

Certain statements in this press release are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact (including, but not limited to, statements to the effect that Toga Limited or its management (the “Company”) “anticipates,” “plans,” “estimates,” “expects,” or “believes,” or the negative of these terms and other similar expressions) should be considered forward-looking statements, including, without limitation, statements regarding the Company’s guidance, outlook, growth, opportunities and long-term strategy. These statements involve certain risks and uncertainties that may cause actual results to differ materially from expectations as of the date of this release. These risks and uncertainties include, without limitation, risks associated with the impact of the COVID-19 pandemic; the Company’s ability to execute on its long-term strategy; the Company’s ability to successfully compete in its intensely competitive industry; the Company’s ability to manage its growth; the Company’s ability to maintain or improve its operating margins; the Company’s ability to identify and react to trends in consumer preferences; product supply disruptions; general economic conditions; accounting standard changes; and other factors as set forth from time to time in the Company’s Securities and Exchange Commission filings, including, without limitation, the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company intends these forward-looking statements to speak only as of the time of this Press Release and does not undertake to update or revise them as more information becomes available, except as required by law.

Researchers Begin Trials of COVID-19 Nasal Spray Vaccine

SYDNEY – Researchers in Australia are starting clinical trials of a new type of COVID-19 vaccine — a nasal spray. Scientists at Brisbane’s Nucleus Network believe that the treatment could be more effective against the virus than the AstraZeneca and Pfizer drugs and that it would allow patients who are afraid of needles to be inoculated.

Despite concerted public health campaigns, the vaccination program in Australia has been slow compared with those of other countries. There have been supply problems, complaints about poor planning by the government and, with the country’s relatively low level of coronavirus cases, complacency and hesitancy in the community.

Australia is accelerating its inoculation rollout. In the future, vaccines could be administered more easily — as a nasal spray designed to “attack the virus” as it enters the body.

Dr. Paul Griffin, medical director at the Nucleus Network, a research organization that’s beginning trials of the nasal therapy, said that while other drugs mostly protect against developing severe symptoms of COVID-19, this one aims to reduce the risk of infection.

“The main benefit is, when we give the vaccine via the same route that the pathogen or the virus gets in through, then hopefully the response will be more adept at actually stopping the virus getting in,” he said. “So, we will get a response that is particularly active at that site, which will hopefully mean that people are much less likely to get infected, which is something that we really want to see with vaccines for this virus.”

An independent ethics committee has approved the Australian trial. Researchers say the nasal spray could be available in a year or two.

Two COVID-19 vaccines — AstraZeneca and Pfizer — are currently approved for use in Australia. This week, health authorities said the AstraZeneca drug would now be recommended for use in people 60 and older, after they received new advice from the country’s vaccine experts about the risk of rare blood clots.

The government plans to vaccinate every Australian who wants to be inoculated by the end of 2021. Australia has recorded about 30,000 coronavirus cases. More than 900 people have died.

Source: Voice of America

Africa Appeals for Vaccines to Combat Third Wave of COVID-19

GENEVA – African health officials are urgently appealing for vaccines to combat a third wave of COVID-19 surging across the continent.

The World Health Organization reports the number of African COVID-19 cases has exceeded 5 million and the disease has killed 136,000 people.

WHO regional director for Africa Matshidiso Moeti says cases have been increasing over the past four weeks. She says new cases in the past week have risen by nearly 30% across the continent and deaths have increased by 15%.

She says five countries—South Africa, Tunisia, Zambia, Uganda, and Namibia—account for 76% of new coronavirus infections in Africa.

“Africa is in the midst of a full-blown third wave. The sobering trajectory of surging cases should rouse everyone to urgent action,” said Moeti. “We’ve seen in India and elsewhere how quickly COVID-19 can rebound and overwhelm health systems. Public health measures must be scaled up fast to find, test, isolate and care for patients and to quickly trace and isolate their contacts.”

Moeti says it is urgent that Africa quickly receive more vaccines as the circulation of more contagious variants across the continent is accelerating. She says the Delta variant, the most virulent strain, has been reported in 14 African countries, and the Beta and Alpha variants have been found in more than 25 countries.

She says 12 million people in Africa now are fully vaccinated against COVID-19. She welcomes the receipt of vaccine doses from the COVAX sharing facility, an initiative co-led by Gavi, the WHO and CEPI.

However, she says those 12 million people represent less than 1% of Africa’s 1.3 billion population.

“At the continental level, we are seeing a rise in cases similar to the first wave peak in July 2020 and about 50% of the second wave peak in January 2021. … Africa needs millions more doses here and now to curb the third wave, and best practice approaches will be key to make the most of the available vaccines,” said Moeti.

WHO says Africa needs 200 million vaccine doses by the end of September to inoculate 10% of the population against the coronavirus. The European Union has pledged to donate 100 million doses to low-income countries and the United States has said it would provide 80 million doses to poorer countries.

Source: Voice of America